DURAVYU has established safety and efficacy data from both Phase 1 and 2 trials in wet AMD and DME that demonstrate stability in vision and anatomical control with a single dose of DURAVYU. No ...
MedPage Today on MSN
More Evidence that GLP-1s May Reduce Risk of Vision-Robbing Eye Diseases
Significantly lower AMD risk compared with other agents in cohort study ...
Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc.
MedPage Today on MSN
GLP-1 Drug Linked to Cases of Rare Vision-Altering Condition
Resolution occurred after stopping dulaglutide, no obvious clues to mechanism ...
A new study published in the Journal of the American Medical Association found that administration of anti–vascular ...
Healthy Vision Month in May is a great time for Texans to focus on protecting their vision health and preventing eye disease. To keep eyes healthy, schedule regular eye exams to check for common ...
PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology, has reported the ...
Many common conditions linked to aging develop without symptoms for years. Learn which five pose the biggest risks and the ...
According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...
PulseSight Therapeutics has unveiled positive phase 1 results for PST‑611, its non‑viral gene therapy candidate for dry ...
But when the retina is damaged, vision can slowly become blurred, distorted or permanently lost, often before a person even ...
Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results